Introduction {#s1}
============

Substantial evidence from human and animal studies has linked the neurotrophic factor neuregulin 1 (NRG1) to the pathophysiology of schizophrenia ([@CIT0075]; [@CIT0065]; [@CIT0012]; [@CIT0002]). The majority of identified polymorphisms are located in the non-coding region of the *NRG1* gene. This suggests a change in NRG1 isoform expression levels, rather than a change in the amino acid sequence of the proteins themselves ([@CIT0012]). Post-mortem analyses of NRG1 mRNA and protein expression levels in the prefrontal cortex (PFC) and hippocampus have reported increased, decreased, and unchanged levels of NRG1 isoforms and altered isoform type ratios in patients with schizophrenia ([@CIT0031]; [@CIT0030]; [@CIT0044]; [@CIT0008]; [@CIT0017]; [@CIT0005]). While differences in NRG1 expression vary between patients, the findings suggest altered NRG1 signaling in the schizophrenia pathophysiology.

Genetic animal models with previously identified or novel mutations in the *NRG1* gene have been developed ([@CIT0052]). These modifications resulted in schizophrenia-relevant behavioral (e.g. hyperlocomotion and sensorimotor gating impairments) and neurochemical (e.g. altered glutamate and γ-aminobutyric acid \[GABA\] neurotransmission) impairments ([@CIT0075]; [@CIT0037]; [@CIT0040]; [@CIT0016]; [@CIT0072]; [@CIT0051]; [@CIT0056]; [@CIT0082]). Furthermore, differences in brain NRG1 expression have been identified in several schizophrenia-relevant rodent models ([@CIT0020]; [@CIT0068]; [@CIT0069]; [@CIT0076]). The rodent studies indicate that changes to NRG1 signaling have functional consequences relevant to the schizophrenia pathophysiology.

The neurotrophic factor NRG1 is expressed throughout the nervous system, with expression levels strongly influenced by neuronal activity ([@CIT0035]). Recent research has identified an involvement of NRG1 signaling in neurotransmission of the adult brain, such as GABA release ([@CIT0080]; [@CIT0016]), GABA receptor currents ([@CIT0080]; [@CIT0016]), and receptor expression levels ([@CIT0063]; [@CIT0003]; [@CIT0056]). Furthermore, glutamate release ([@CIT0029]; [@CIT0066]; [@CIT0082]) and N-Methyl-D-aspartic acid (NMDA) receptor functions are also reportedly influenced by NRG1 signaling ([@CIT0029]; [@CIT0009]; [@CIT0006]; [@CIT0066]). The neurotransmission effects of NRG1 appear to be primarily mediated through the epidermal growth factor receptor tyrosine kinase ERBB4, but might also involve other epidermal growth factor receptor tyrosine kinase (ERBB) receptor isoforms ([@CIT0034]; [@CIT0054]). ERBB4 is expressed on GABAergic interneurons and glia in the PFC and hippocampus ([@CIT0024]; [@CIT0049]; [@CIT0013]; [@CIT0022]; [@CIT0062]), with other ERBB isoforms expressed throughout the central and peripheral nervous system ([@CIT0034]). The *in vitro* studies suggest that NRG1 signaling is involved in neurotransmission relevant to schizophrenia pathophysiology, potentially contributing to differences observed in the GABAergic and glutamatergic neurotransmitter systems in patients ([@CIT0057]; [@CIT0033]). However, the consequence of altered NRG1 signaling on schizophrenia-relevant neurotransmission differences has not yet been explored.

Genetic animal models and *in vitro* studies indicate a role for NRG1 signaling in schizophrenia, but how NRG1 affects schizophrenia-relevant behavior and neurotransmission (particularly GABAergic and glutamatergic) in adult animals is unknown. To address this question, we treated adult mice with the extracellular signaling domain of NRG1 and assessed spontaneous behavior (locomotor activity and acoustic startle response), as well as extracellular neurotransmitter levels (GABA, glutamate, and glycine). Furthermore, we asked whether the effect of NRG1 would differ under schizophrenia-relevant impairments in mice, since differences in NRG1 expression levels have been found in patients with schizophrenia. We therefore co-treated mice with NRG1 and phencyclidine (PCP), a commonly used substance for modeling schizophrenia-like behavioral and neurotransmission impairments in rodents ([@CIT0001]; [@CIT0036]; [@CIT0058]; [@CIT0067]). With our experiments we show that NRG1 treatment prevented PCP-induced impairments, which gives rise to the idea of NRG1 having antipsychotic-like properties.

Methods {#s2}
=======

Animals {#s3}
-------

Ten-week-old male C57BL6j mice were purchased from Animal Resource Centre for locomotor activity and microdialysis experiments and Australian BioResources for sensorimotor gating experiments. Animals were group-housed in open-lid cages with minimal enrichment (M1 polypropylene cages; Able Scientific) and maintained on a 12h light/dark cycle (light on at 0600 hours) with food and water available *ad libitum* in the animal facilities of the University of Wollongong (open field and microdialysis experiments) and Neuroscience Research Australia (sensorimotor gating experiments). All research and animal care procedures were approved by either the Animal Ethics Committee of the University of Wollongong (AE10/07 and AE11/18) or University of New South Wales (4149794) and were in agreement with the Australian Code of Practice for the Care and Use of Animals for Scientific Purposes. Mice were acclimatized for at least one week prior to experiments. For behavioral studies, testing order was pseudo-randomized to account for diurnal variations. For microdialysis studies, testing order was constant to allow the comparison of molecular responses.

Drugs {#s4}
-----

All compounds were obtained from Sigma except where specified otherwise. Drugs were freshly prepared on each treatment day. Recombinant human NRG1 (NRG1-β1/HRG1-β1 EGF domain CF; R&D Systems) and PCP were dissolved in either artificial cerebrospinal fluid (ACSF, 119mM NaCl; 2.5mM CaCl~2~; 2.5mM KCl; 1.3mM MgSO~4~; 1mM NaH~2~PO~4~; 26.2mM NaHCO~3~; 11mM glucose, 7.4 pH, 290 mOsm/kg) for i.c.v. injections and retrodialysis or in 0.9% NaCl (vehicle) for i.p. injections. For behavioral testing, each mouse received no more than three treatments with an inter-test interval of one week.

Open Field Behavior {#s5}
-------------------

The receptors for NRG1 are expressed throughout the nervous system and have also been found on muscle tissue ([@CIT0085]; [@CIT0007]; [@CIT0078]). Peripheral NRG1 treatment might therefore directly affect muscle cells, masking possible central nervous system responses. Independent open field experiments with i.c.v. and i.p. NRG1 administration were therefore performed.

Intracerebroventricular Cannula Implantation {#s6}
--------------------------------------------

Mice destined for i.c.v. treatment underwent surgical implantation of an i.c.v. cannula one week prior to experiments. Animals were anaesthetized with an inhalation 1.5% isoflurane (Delvet)/98.5% oxygen mix. Using a stereotactic frame (Kopf Instruments), a 21 G guide cannula was implanted into the brain, targeting the right lateral ventricle (Bregma -0.25mm rostral, -1mm medial, -1.5mm from top of skull; [@CIT0064]). The guide cannula was fixed to the skull with anchor screws (2mm, Microbiotech) and dental acrylic (Ketac Cem, Halas Dental Limited). All animals were injected with 0.1ml of a depot-antibiotic substance (Medicam, Boehriner Ingelheim) and additionally received it in their drinking water (0.1%) for three days following surgery. Dummy cannula (28 G), were inserted into the guide to keep it clean and prevent occlusion. Following surgery, mice were individually housed and their recovery was monitored daily until the behavioral experiments commenced.

Locomotion After Treatment {#s7}
--------------------------

Mice were habituated to a round open field arena (40cm diameter) for 30min before i.p. and/or i.c.v. injections, and re-exposed to the open field for 30min thereafter. For the i.p. experiments, all animals (n = 8/group) received an i.p. injection of NRG1 (5, 25, or 50 µg/kg), PCP (3mg/kg), PCP + NRG1 (5, 25, or 50 µg/kg), or vehicle. For the i.c.v. experiments, all animals (n = 6--8/group) received an i.c.v. injection of NRG1 (3, 30, or 300ng/kg) or ACSF and simultaneously an i.p. injection of PCP (3mg/kg) or vehicle. NRG1 concentrations were selected below reported sedative levels ([@CIT0073]). Distance traveled was recorded before and after injections using the EthoVision tracking system (Noldus). Activity data were collected in 5min intervals, with individual post-treatment distance traveled normalized to the habituation performance.

Sensorimotor Gating {#s8}
-------------------

Sensorimotor gating (i.e. pre-pulse inhibition of startle response) was assessed as previously published ([@CIT0038]). Briefly, one week before testing, mice (n = 8/group) were allowed 30min habituation to the prepulse inhibition (PPI) chambers at background noise levels (70 dB; SR-LAB; San Diego Instruments). Animals received an i.p. injection of NRG1 (5, 25, or 50 µg/kg), PCP (3mg/kg), PCP + NRG1 (5, 25, or 50 µg/kg), or vehicle directly following a 5min re-acclimatization period in the PPI chambers. Sensorimotor gating was tested in 100 trials over 25min, consisting of 3 startle response blocks and PPI response trails (pre-pulse intensities: 74 dB, 82 dB, and 86 dB),

Microdialysis and Amino Acid Quantification {#s9}
-------------------------------------------

Microdialysis was performed as described previously ([@CIT0043]). Briefly, similar to the i.c.v. cannula implantation, a microdialysis guide cannula (MAB 6.14.IC Microbiotech/SE) was surgically implanted into either the medial PFC or dorsal CA1 to accommodate a microdialysis probe. Mice were individually housed in purpose-built microdialysis cages (25 x 25 x 40cm, grey Polyvinyl chloride (PVC) with clear front) for all experimental procedures, which allowed free access to food and water. After seven days of recovery, the microdialysis probe (1mm membrane length, 15kDa cut off, MAB 6.14.1, Microbiotech) was inserted into the guide cannula and lowered into the respective target area of the right mPFC/dCA1 2.5h before the first treatment. It was connected via low volume in- and outflow tubing (FEP-tubing, 4001004, Microbiotech; fluid swivel 375/D/22QM, Instechlabs) via a counter-balanced lever arm to a syringe pump (1 µl/min, Harvard Instruments). Microdialysis samples were collected in 10min intervals 2.5h after probe insertion. Animals received 10min infusions with NRG1 (10nM), PCP (10 µM), and NRG1 + PCP, separated by 2.5h of ACSF each. Potassium-stimulated neurotransmitter release ([@CIT0074]) and probe placement were confirmed before data analysis.

Gas Chromatography Mass Spectrometry Sample Processing and Analysis {#s10}
-------------------------------------------------------------------

Derivatization followed a previously published method ([@CIT0021]). Briefly, samples were supplemented with heavy isotopes (20 pmole GABA-*d6*, 200 pmole Glycine-*C13-2, N15*, 2 pmole Glutamate-*d5*) and diluted in acetonitrile/methanol (1:1) before centrifugation. The supernatant was dried off at 37°C under nitrogen before derivatization with pentafluoropropionic acetic anhydride and 2,2,3,3,3-pentafluoro-1-propanol (PM Separations PTY). Following derivatization, samples were resuspended in toluene for analysis. Samples were analyzed using negative chemical ionization in a gas chromatograph with triple quad mass spectrometry (GC-MS/MS, 7000B & 7890A, Agilent Technologies). Specific multiple-reaction monitoring transitions were performed to monitor the glutamate ion transition m/z 379.0 → m/z 188.0, qualifier transitions (m/z 537.0 → m/z 313.0 and m/z 537.0 → m/z 217.0), and m/z 542 → m/z 221 for the corresponding isotopic *d* ~5~ labeled internal standard. GABA ion transition was detected at m/z 191.1 → 109.0, qualifier transitions (m/z 321.0 → m/z 301.0 and m/z 341.0 → m/z 208.0), and m/z 327 → m/z 306 for the corresponding isotopic *d* ~6~ labeled internal standard. Glycine ion transition was detected at m/z 333.0 → m/z 313.0, qualifier transitions at m/z 333.0 → 200.0 and m/z 365.0 → 232.0, and m/z 336.0 → m/z 316.0 for the corresponding isotopic *C13-2* labeled internal standard. The area under the curve for peaks of GABA, glutamate, and glycine were normalized by their respective internal standard peaks, followed by normalization to the relevant baseline samples.

Statistical Analysis {#s11}
--------------------

Pre- and post-injection locomotor activity and startle following pulse-only trails were assessed by a one-way analysis of variance (ANOVA), followed by a Bonferroni's multiple comparison post hoc analysis when required. Single time point differences in distance traveled were assessed by one-way ANOVA for repeated measurements, followed by Bonferroni's multiple comparison post hoc analysis. Differences in PPI were assessed using two-way repeated-measures ANOVA (treatment x pre-pulse intensity), followed by Bonferroni's multiple comparison post hoc analysis. Treatment effects on neurotransmitter levels were assessed using Linear Mixed Model (LMM) on repeated measurements for each brain area and transmitter following baseline normalization. Overall differences in extracellular neurotransmitter levels were assessed by calculating the area under the curve (AUC) for the entire sampling period using the trapezoidal rule. AUC and single time point differences were assessed by one-way ANOVA for repeated measurements, followed by Tukey's post hoc analysis where appropriate. Analyses were performed using SPSS 19.0 (IBM). Statistical significance was accepted at *p* \< 0.05 and data are presented as the mean ± standard error of the mean.

Results {#s12}
=======

NRG1 Treatment Does Not Alter Locomotor Activity, But Prevents PCP-Induced Hyperlocomotion {#s13}
------------------------------------------------------------------------------------------

Increased spontaneous locomotor activity in the open field arena is considered to be an indirect measure of hyperdopaminergic and hypoglutamateric tone experienced by patients with schizophrenia during a psychotic episode ([@CIT0001]) and reported from several NRG1 genetic animal models ([@CIT0052]).

Locomotor activity differed significantly between treatment groups (*F* ~7,\ 54~ = 7.35, *p* \< 0.001), with activity of i.p. NRG1-treated mice being similar to vehicle-treated mice (5 µg/kg: *p* = 0.22, 25 µg/kg and 50 µg/kg: *p* = 0.99 vs vehicle; [Figure 1A](#F1){ref-type="fig"}). Mice treated with PCP showed an increase in locomotor activity (*p* = 0.003 vs vehicle; [Figure 1A](#F1){ref-type="fig"}), consistent with previous studies ([@CIT0026]; [@CIT0059]). Combining PCP with NRG1 i.p. altered the PCP-induced increase in locomotor activity in a concentration-dependent manner. NRG1 at 25 μg/kg, but not at 5 or 50 µg/kg, prevented the PCP hyperlocomotive effect (*p* = 0.02 vs PCP, 5 μg/kg: *p* = 0.99, 50 μg/kg: *p* = 0.79 vs PCP; [Figure 1A](#F1){ref-type="fig"}).

![Peripheral and central administered neuregulin 1 (NRG1) prevents PCP-induced hyperlocomotion in mice. (A & B) Post-treatment distance moved as percentage of habituation locomotion for varying doses of i.p. NRG1 (A, µg/kg) or i.c.v. NRG1 (B, ng/kg), administered in combination with PCP (3mg/kg) or vehicle (A, 0.9% NaCl; B, artificial cerebrospinal fluid + 0.9% NaCl). Data is presented as mean percentage difference to habituation locomotion + standard error of the mean (n = 8/group). (C & D) Mean distance moved within 5min windows pre- and post-treatment ± standard error of the mean (n = 8/group) after (C, i.p.) vehicle, NRG1 (25 μg/kg), PCP, or NRG1 + PCP (25 μg/kg + 3mg/kg); (D, i.c.v. + i.p.) vehicle, NRG1 (30ng/kg + 0.9% NaCl), PCP (artificial cerebrospinal fluid + 3mg/kg), or NRG1 + PCP (30ng/kg + 3mg/kg). \**p* \< 0.05, \*\**p* \< 0.01 *vs* PCP; \#*p* \< 0.01, \#\#*p* \< 0.001, \#\#\#*p* \< 0.0001 vs vehicle.](ijnppy_pyu114_f0001){#F1}

One-way ANOVA also revealed a significant treatment effect on locomotor activity of i.c.v. treated mice (*F* ~6,\ 43~ = 6.6, *p* \< 0.001). Locomotor activity following i.c.v. NRG1 treatment was similar to vehicle-treated animals (*p =* 0.99 for 30ng/kg and 300ng/kg vs vehicle; [Figure 1B](#F1){ref-type="fig"}). PCP treatment again increased locomotor activity (*p* \< 0.001 vs vehicle; [Figure 1B](#F1){ref-type="fig"}). Similar to i.p. treatment, NRG1 i.c.v. altered the PCP effect in a concentration-dependent manner. NRG1 at 30ng/kg, but not at 3 or 300ng/kg, prevented PCP-induced hyperlocomotion (*p* = 0.024 vs PCP; 3ng/kg and 300ng/kg: *p* = 0.99 vs PCP; [Figure 1B](#F1){ref-type="fig"}).

Comparing the distance traveled for each post-treatment interval via repeated-measure two-way ANOVA (i.p. NRG1 Treatment *F* ~3,\ 28~ = 2.93, *p* = 0.05; i.c.v. NRG1 Treatment *F* ~3,\ 28~ = 8.88, *p* \< 0.001) showed that PCP treatment triggered hyperlocomotion within 10min post-treatment (*p* = 0.002 vs vehicle, [Figure 1C](#F1){ref-type="fig"} and [D](#F1){ref-type="fig"}). Combined treatment with either i.p. 25 μg/kg NRG1 ([Figure 1C](#F1){ref-type="fig"}) or i.c.v. 30ng/kg NRG1 ([Figure 1D](#F1){ref-type="fig"}) prevented the increase in locomotor activity from the treatment onset ([Figure 1C](#F1){ref-type="fig"} and [D](#F1){ref-type="fig"}), while NRG1 treatment in the absence of PCP did not alter locomotor activity.

NRG1 Treatment Prevents PCP-Induced Deficit of Pre-Pulse Inhibition of Startle {#s14}
------------------------------------------------------------------------------

Patients with schizophrenia show impaired sensorimotor gating ([@CIT0011]), which can be tested in rodents through inhibition of startle response experiments ([@CIT0011]). In our sensorimotor gating experiment, startle response to a 120 dB pulse was not affected by any of the treatments (*F* ~7,\ 58~ = 1.5, *p* = 0.18; [Figure 2A](#F2){ref-type="fig"}). Pre-pulse intensity had a significant effect on PPI for vehicle-treated animals (*F* ~1.2,\ 8.5~ = 69.52, *p* \< 0.001; [Figure 2B](#F2){ref-type="fig"}). Furthermore, PPI differed significantly between treatment groups (*F* ~6,\ 45~ = 5.55, *p* \< 0.001). NRG1 treatment at 25 μg/kg and 50 μg/kg had no effect on PPI performance (*p* \> 0.8 vs vehicle), while 5 µg/kg NRG1 impaired the PPI effect at 74 and 82 dB pre-pulse intensity (*p* = 0.01 and *p* = 0.03 vs vehicle, respectively; [Figure 2B](#F2){ref-type="fig"}). PCP treatment impaired PPI for all three pre-pulse intensities (74 dB: *p* = 0.01, 82 dB: *p* \< 0.001, and 86 dB: *p* = 0.002 vs vehicle; [Figure 2B](#F2){ref-type="fig"}), which is consistent with previous studies ([@CIT0004]; [@CIT0081]). NRG1 prevented the PCP-induced disruption of PPI for pre-pulses of 82 and 86 dB in a dose-dependent manner (25 µg/kg NRG1 at 82 dB: *p* = 0.006; at 86 dB: *p* = 0.04; 50 µg/kg NRG1 at 82 dB: *p* = 0.02; [Figure 2B](#F2){ref-type="fig"}). The ability of NRG1 to prevent PCP-induced sensorimotor gating impairment indicates an acute influence over several schizophrenia-relevant neurotransmitter systems.

![Peripheral neuregulin 1 (NRG1) injection prevents PCP-induced prepulse inhibition (PPI) impairment. Mice (n = 7--8/group) treated intraperitoneally with vehicle, NRG1 (5, 25, or 50 μg/kg), PCP (3mg/kg), or NRG1 + PCP (5, 25, or 50 μg/kg NRG1 + 3mg/kg PCP). (A) Treatments had no effect on startle response to 120 dB pulses (one-way analysis of variance, *F* ~7,\ 58~ = 1.502, *p* = 0.18). Values are presented as mean of startle intensity + standard error of the mean. (B) Treatment effect on PPI following different prepulse intensities. Values are presented as mean percentage of PPI + standard error of the mean. \#*p* \< 0.05, \#\#*p* \< 0.01, \#\#\#*p* \< 0.001 vs vehicle (veh); \**p* \< 0.05, \*\**p* \< 0.01 vs PCP.](ijnppy_pyu114_f0002){#F2}

NRG1 Reduces Glutamate and Glycine Levels in the Mouse PFC *In Vivo* {#s15}
--------------------------------------------------------------------

The microdialysis experiment was designed to assess the consequence of increased NRG1 signaling on schizophrenia-relevant neurotransmission under healthy and impaired conditions. We first measured GABA, glutamate, and glycine levels in the PFC following NRG1 retrodialysis and combined with PCP. The retrodialysis treatments had a significant overall effect on extracellular glutamate and glycine levels (LMM: glutamate: *F* ~3,\ 145.8~ = 11.41, *p* \< 0.001; glycine: *F* ~3,\ 145.1~ = 6.85, *p* \< 0.001), without affecting overall GABA levels (GABA: *F* ~3,\ 123.9~ = 0.55, *p* = 0.64). By comparing single time point GABA levels, we identified an increase 10min after NRG1 treatment (194.0±47.0% of baseline, *p* = 0.03; [Figure 3A](#F3){ref-type="fig"}), which returned to baseline levels for the remaining sampling period. PCP infusion reduced extracellular GABA levels 20min after treatment (37.6±8.0% of baseline, *p* = 0.005; [Figure 3A](#F3){ref-type="fig"}). Combined infusion of NRG1 + PCP prevented this reduction of extracellular GABA levels (104.2±45%, *p* \> 0.99 vs baseline; [Figure 3A](#F3){ref-type="fig"}). GABA levels expressed as AUC revealed that none of the three treatments affected overall GABA concentration across the sampling period (*F* ~3,\ 18.6~ = 0.9, *p* = 0.46; [Figure 3B](#F3){ref-type="fig"}).

![Neuregulin 1 (NRG1) reduces extracellular glutamate and glycine in the prefrontal cortex (PFC) *in vivo*. Mice (n = 8--10/treatment) received a local infusion of NRG1 (10nM), PCP (10 µM), or NRG1 + PCP for 10min in the PFC by retrodialysis. Extracellular GABA (A & B), glutamate (C & D), and glycine (E & F) levels are expressed as a percentage of the respective mean baseline value ± standard error of the mean for each time point (A, C, E) or baseline equivalent for area under the curve analysis (B, D, F). Dotted lines indicate baseline levels before each treatment. \**p \<* 0.05 NRG1 + PCP vs baseline; ^\#^ *p* \< 0.05 PCP vs baseline; ^+^ *p* \< 0.05, ^++^ *p* \< 0.01 NRG1 vs baseline.](ijnppy_pyu114_f0003){#F3}

NRG1 infusion reduced extracellular glutamate levels in the PFC throughout the sampling period (LMM: 50.8±10.2% of baseline, *p* \< 0.001; AUC: 52.2±9.8% of baseline, *p* = 0.005; [Figure 3C](#F3){ref-type="fig"} and [D](#F3){ref-type="fig"}). However, neither PCP nor NRG1 + PCP affected glutamate levels at single time points or during the entire sampling period (LMM: *p* = 0.69 and *p* \> 0.99 vs baseline, AUC: *p* = 0.81 and *p* = 0.65 vs baseline, respectively; [Figure 3C](#F3){ref-type="fig"} and [D](#F3){ref-type="fig"}). Overall, extracellular glycine levels were reduced following NRG1 infusion (AUC: 57.5±9.8% of baseline, *p* = 0.008; [Figure 3E](#F3){ref-type="fig"} and [F](#F3){ref-type="fig"}). Glycine levels were not affected by PCP (AUC: *p* = 0.98 vs baseline). Combined NRG1 + PCP treatment led to a marked increase in glycine levels during the infusion period (219.0±61.0% of baseline, *p* = 0.02; [Figure 3E](#F3){ref-type="fig"}). This increase did not persist for the remaining sampling period (AUC: 125.1±10.4% of baseline, *p* = 0.11). The PFC microdialysis experiment shows that NRG1 has an immediate influence on extracellular neurotransmitter levels with potential relevance to schizophrenia.

NRG1 Reduces Glutamate and Glycine Levels and Prevents PCP-Induced GABA Increase in the Hippocampus *In Vivo* {#s16}
-------------------------------------------------------------------------------------------------------------

Impaired signaling between the hippocampus and PFC has been implicated in the pathophysiology of schizophrenia ([@CIT0027]). We therefore further investigated the effect of NRG1 increase on hippocampal neurotransmitter levels. In the dorsal CA1 of the hippocampus, the retrodialysis treatments had a significant effect on overall extracellular glutamate and glycine levels (glutamate: *F* ~3,\ 158.9~ = 16.85, *p* \< 0.001; glycine: *F* ~3,\ 159.~1 = 6.68, *p* \< 0.001), but only affected GABA levels at single time points (*F* ~3,\ 147.4~ = 1.39, *p* = 0.248). NRG1 showed a tendency to increase GABA levels during the infusion period (212.0±66.0% of baseline, *p* = 0.1), with post-infusion samples remaining close to baseline ([Figure 4A](#F4){ref-type="fig"}). PCP significantly increased extracellular GABA concentration during the 10min infusion period (313.0±82.8% of baseline, *p* = 0.01; [Figure 4A](#F4){ref-type="fig"}). Co-infusion of NRG1 prevented the PCP effect (103.0±16.0% of baseline, *p =* 0.96; [Figure 4A](#F4){ref-type="fig"}). AUC analysis showed a trend in overall treatment effect on GABA levels (*F* ~3,19.9~ = 2.8, *p* = 0.07), with a trend towards reduced overall GABA levels following NRG1 + PCP (NRG1: *p* = 0.31; PCP: *p* \> 0.99; NRG1 + PCP: *p* = 0.07 vs baseline; [Figure 4B](#F4){ref-type="fig"}).

![Neuregulin 1 (NRG1) prevents PCP-induced increase in GABA levels and reduces extracellular glutamate in the presence of PCP in the dorsal hippocampus CA1 (dCA1) *in vivo*. Mice (n = 8--10/treatment) received a local infusion of NRG1 (10nM), PCP (10 µM), or NRG1 + PCP for 10min in the dCA1 by retrodialysis. Extracellular GABA (A & B), glutamate (C & D), and glycine (E & F) levels are expressed as a percentage of the respective mean baseline value ± standard error of the mean for each time point (A, C, E) or baseline equivalent for area under the curve analysis (B, D, F). Dotted lines indicate baseline levels before each treatment. ^T^\**p* = 0.07, \**p* \< 0.05, \*\**p* \< 0.001 NRG1 + PCP vs baseline; ^T\#^ *p* = 0.06, ^\#^ *p* \< 0.05^,\ \#\#^ *p* \< 0.01 PCP vs baseline; ^T+^ *p* = 0.07, ^+^ *p* \< 0.05, ^++^ *p* \< 0.001 NRG1 vs baseline.](ijnppy_pyu114_f0004){#F4}

Glutamate levels were reduced 10min after NRG1 treatment for 20min (10 min: 54.9±8.9% of baseline, *p* = 0.006; 20 min: 61.7±7.9%, *p* \< 0.007; 30 min: 37.7±4.3%, *p* \< 0.001; [Figure 4C](#F4){ref-type="fig"}). PCP increased extracellular glutamate levels 20min after treatment (135.3±10.8% of baseline, *p* = 0.06; [Figure 4C](#F4){ref-type="fig"}). Combined treatment of NRG1 + PCP reduced glutamate levels during the infusion period (28.0±9.0% of baseline, *p* \< 0.001), with levels remaining below baseline until 50min after treatment ([Figure 4C](#F4){ref-type="fig"}). The combined treatment therefore prevented the 20min PCP peak (70.0±10.2% of baseline, *p* \< 0.001 vs PCP). The AUC analysis (*F* ~3,\ 23.2~ = 5.92, *p* = 0.004) confirmed this observation, with NRG1 and NRG1 + PCP leading to glutamate levels below baseline values (64.3±9.2%, *p* = 0.07 and 53.2±12.6%, *p* = 0.01 [vs]{.ul}baseline, respectively; [Figure 4D](#F4){ref-type="fig"}).

Hippocampal glycine levels were unaffected by NRG1 infusion throughout the sampling period (LMM: *p* = 0.17; [Figure 4E](#F4){ref-type="fig"}). PCP infusion caused an increase in extracellular glycine levels 50min after treatment (186.5±47.0% of baseline, *p* \< 0.05; [Figure 4E](#F4){ref-type="fig"}). However, combined infusion of NRG1 + PCP increased glycine levels during the infusion period (196.0±58.0% of baseline, *p* = 0.047, [Figure 4E](#F4){ref-type="fig"}). None of the treatments affected overall glycine levels compared to baseline ([Figure 4F](#F4){ref-type="fig"}).

Discussion {#s17}
==========

In the present study, we showed that NRG1 treatment: (1) did not affect spontaneous behavior, but prevented PCP-induced behavioral impairments in the open field and prepulse inhibition paradigms; (2) reduced extracellular glutamate and glycine levels in the PFC and hippocampus; and (3) prevented PCP-induced changes to extracellular GABA levels in the hippocampus. With these results we provide the first compelling *in vivo* evidence for the involvement of NRG1 in schizophrenia-relevant behavior and neurotransmission and its treatment potential.

NRG1 Treatment Does Not Affect Spontaneous Behavior, But Prevents PCP-Induced Impairments {#s18}
-----------------------------------------------------------------------------------------

NRG1 administration did not adversely affect performance in the behavioral paradigms tested. Mice receiving central or peripheral NRG1 injections traveled a similar distance as vehicle-treated mice, and no difference in spontaneous behavior was observed. This finding is in line with a published study which reports no difference in locomotor activity 24h and 28d after two days of subcutaneous NRG1 (166 µg/kg) treatment in mice ([@CIT0053]). Experiments with genetic animals have shown that reduced NRG1 (e.g. reducing ERBB or NRG1 expression) or increased NRG1 signaling (e.g. overexpression of NRG1 type I) leads to hyperactivity in the open field arena ([@CIT0037]; [@CIT0040]; [@CIT0016]; [@CIT0051]; [@CIT0082]). While acute application of NRG1 had no effect on locomotion, chronically altering the NRG1 signaling pathway likely caused the locomotor differences in genetically-modified animals, instead of short-term effects of NRG1 on related neurotransmission.

Several NRG1 transgenic animal models show sensorimotor gating impairments ([@CIT0015]; [@CIT0018]; [@CIT0016]; [@CIT0038]). We therefore assessed the acoustic startle response following NRG1 treatment in wild type mice. Neither startle response nor PPI performance was affected by 25 or 50 μg/kg NRG1 compared to vehicle, while 5 μg/kg reduced the PPI effect. These results suggest that sensorimotor gating differences caused by genetically modifying the NRG1 signaling pathway are not related to acute NRG1 signaling. Furthermore, the dose-dependent behavioral response indicates that minor imbalances in NRG1 signaling potentially contribute to the disorder phenotype.

To explore the consequence of increased NRG1 signaling on schizophrenia-relevant behavioral impairments, we administered NRG1 to mice also receiving PCP. Consistent with previous publications, PCP treatment induced hyperlocomotion and impaired PPI ([@CIT0004]; [@CIT0026]; [@CIT0059]). We subsequently discovered that NRG1 treatment dose-dependently prevented the PCP-induced hyperlocomotion and PPI impairment ([Figures 1](#F1){ref-type="fig"} and [2B](#F2){ref-type="fig"}). The PCP-rodent model is commonly used for identifying substances with antipsychotic-like potential ([@CIT0001]). Current antipsychotics, including olanzapine, clozapine, and haloperidol, have been shown to prevent PCP-induced hyperlocomotion and PPI impairments ([@CIT0004]; [@CIT0026]; [@CIT0011]; [@CIT0046]; [@CIT0052]). By preventing PCP-induced behavior impairments, NRG1 treatment shows antipsychotic-like potential. Remarkably, NRG1 i.c.v. and i.p. administrations had comparable outcomes against PCP-induced hyperlocomotion, which suggests that peripheral NRG1 administration has neuromodulatory properties on central receptors. This observation supports previous studies, which have shown that peripherally-administered recombinant NRG1 can readily cross the blood-brain barrier ([@CIT0039]; [@CIT0041]; [@CIT0071]).

NRG1 Reduces Glutamate and Glycine Levels and Prevents PCP-Induced GABA Increase *In Vivo* {#s19}
------------------------------------------------------------------------------------------

In the brain, the NRG1 receptor ERBB4 is predominantly located on GABAergic interneurons, with high expression in the PFC and hippocampus ([@CIT0022]; [@CIT0062]), which are associated with the behavioral symptoms of schizophrenia ([@CIT0033]). This expression pattern, together with the reported effects of NRG1 on neurotransmission *in vitro*, suggests that NRG1 signaling may influence GABAergic and glutamatergic neurotransmission in the PFC and hippocampus. We therefore assessed the effects of local NRG1 application on extracellular GABA, glutamate, and glycine levels in the PFC and hippocampus *in vivo*. Glutamate and glycine levels in both brain regions were reduced following NRG1 retrodialysis ([Figure 3B](#F3){ref-type="fig"} and [C](#F3){ref-type="fig"} and [Figure 4B](#F4){ref-type="fig"} and [C](#F4){ref-type="fig"}). This effect potentially contributes to the reported reduction in NMDA receptor currents and subunit internalization following NRG1 application in PFC slice preparations ([@CIT0029]). While recent work shows that NRG1 can reduce glutamate release via the pre-synaptic LIMK1 protein ([@CIT0082]), the exact mechanism underlying the present finding is worthy of further investigation.

NRG1 application *in vitro* has been shown to increase depolarization-evoked GABA release in the PFC by activating ERBB4 receptors ([@CIT0080]; [@CIT0016]). Prolonged NRG1 treatment has been shown to reduce surface levels of GABA-A receptors ([@CIT0063]), potentially compensating for the reported increase in GABA release. We observed an increase in GABA levels during the infusion period in the hippocampus and, slightly delayed, in the PFC. Our *in vivo* findings suggest that GABA-releasing cells in the adult nervous system respond to acute NRG1 signaling, adding support to the existing *in vitro* studies.

Deficits in the GABAergic and glutamatergic system have been identified in the PFCs and hippocampi of patients with schizophrenia ([@CIT0028]; [@CIT0061]). We therefore investigated whether the response to NRG1 administration would differ when combined with PCP. PCP treatment caused a short-term increase in GABA levels in the hippocampus. While reduced GABA levels in the PFCs of rodents following PCP infusion have been reported previously ([@CIT0083]; [@CIT0084]), these studies used higher PCP concentrations (10 vs 50 and 100 μM) coupled with longer treatment durations (10 vs 40min), which are likely responsible for the effect difference. Combined NRG1 and PCP infusion completely prevented the PCP-induced increase in GABA levels. The observed effect on GABA by combined NRG1 and PCP treatment occurred during the retrodialysis period, suggesting a direct action on local neurotransmitter release or uptake mechanisms. Notably, a recent study identified an interaction between ERBB4 and GABA-A receptors in hippocampal interneurons, which possibly contributed to the observed NRG1 treatment effect ([@CIT0056]).

In line with existing reports ([@CIT0084]), local PCP infusion in the PFC and hippocampus did not change glutamate or glycine levels. However, glycine levels were markedly increased during the infusion period of NRG1 and PCP in both brain regions, while glutamate levels remained below baseline levels for the sampling period. Since the effect duration differs for both neurotransmitters, separate mechanisms are likely involved. Furthermore, there appears to be no correlation between the treatment effects on the extracellular levels of GABA, glutamate, and glycine. PCP and NRG1 have been reported to alter extracellular dopamine levels *in vivo* ([@CIT0083]; [@CIT0084]; [@CIT0042]). Assessing the effect of the combined treatment on dopamine levels will aid the understanding of mechanisms underlying the effect of NRG1 administration by itself and in the presence of PCP on neurotransmission.

The effect of antipsychotics on local PCP-induced neurotransmitter alterations has not been published. However, local clozapine and haloperidol administration have been reported to reduce GABA levels, with clozapine, but not haloperidol, also increasing glutamate levels in the PFCs of rats ([@CIT0010]; [@CIT0050]). NRG1 infusion changed GABA, glutamate, and glycine levels in the presence of PCP, indicating a potential for NRG1 signaling to acutely alter impaired neurotransmission.

The Potential Implications of Altered NRG1 Signaling in Schizophrenia {#s20}
---------------------------------------------------------------------

Existing *in vitro* experiments have indicated that NRG1 administration is more likely to affect neurotransmitter receptor availability than neurotransmitter release in PFC and hippocampus slice preparations ([@CIT0048]; [@CIT0063]; [@CIT0014]; [@CIT0066]; [@CIT0072]). The observed rapid neurotransmitter level changes following NRG1 and the combined NRG1 and PCP infusion are therefore noteworthy. However, since each sample covers a 10min window, we cannot determine the exact order of neurochemical events, which is of particular relevance since GABA and glycine have been reported to influence glutamate levels ([@CIT0077]; [@CIT0045]). Furthermore, the behavioral response to i.c.v. NRG1 suggests that neurotransmission in other brain regions, such as the striatum, are also rapidly affected.

The effects of NRG1-ERBB4 signaling have been suggested to follow an "inverted-U model" when studying neuronal activity ([@CIT0070]). The dose-dependent response of NRG1 against PCP-induced behavioral impairments indicates a non-linear concentration response. U-shaped behavioral responses have been associated with PFC dopamine levels ([@CIT0032]), and are considered critical for the development of pharmacological agents targeting cognitive symptoms of schizophrenia ([@CIT0055]). However, the bi-phasic dose-response of NRG1 in the present study requires further exploration using a wider concentration range to determine the exact NRG1-ERBB complex relationship. Broadening the concentration spectrum may also shed light on the consequence of altered NRG1 signaling in humans, since both increased and decreased NRG1 expression has been observed in patients with schizophrenia ([@CIT0019]). Furthermore, chronically increased or decreased NRG1 signaling in mice has led to behavioral and structural differences ([@CIT0052]). This highlights the need to assess the NRG1 signaling system at different stages during development. Such investigations will also provide critical information about the onset and duration of a possible NRG1 treatment strategy following our identification of the antipsychotic-like treatment potential. The suitability of NRG1 administration to humans has recently been explored in successful phase II clinical trials in patients with chronic heart failure ([@CIT0016]; [@CIT0035]). Thus, a combination of pre-clinical and clinical data suggests that NRG1 has a therapeutic system-dependent effect, likely within a specific concentration range.

Conclusion {#s21}
==========

In the present study, we showed that acute treatment with NRG1 has little effect on spontaneous behavior, while significantly reducing glutamatergic neurotransmission in the PFC and hippocampus. Importantly, our results demonstrate that NRG1 administration prevents schizophrenia-relevant behavior impairments and disruptions of the GABAergic system caused by PCP. The ability of NRG1 treatment to alter GABA, glutamate, and glycine levels in the presence of PCP also suggests that NRG1 signaling has the potential to alter disrupted neurotransmission in patients with schizophrenia. Our findings are therefore the first step towards exploring the therapeutic potential of NRG1 for the treatment of schizophrenia.
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